These preliminary data prompted us to compare retrospectively a cohort of 21 FLT3–ITD-mutated AML patients receiving sorafenib maintenance after allogeneic HSCT with a control group of 22 FLT3–ITD-mutated AML patients, who did not receive any maintenance treatment. The gene discussed is FLT3; the disease is acute myeloid leukemia.